Physician profile
George Thomas
NPI 1972540870
$6,104.38
in general payments reported to CMS, 2019-2025
40 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $126 · 2021: $83.06 · 2022: $671 · 2023: $1,385 · 2024: $1,443 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,270.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.32 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $691.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $650.86 | 2019-2025 | |
| Novo Nordisk INC | $601.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $350.48 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.67 | 2019-2025 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $230.02 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $193.23 | 2022-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $191.51 | 2019-2025 | Spravato |
| Amgen INC. | $191.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Corcept Therapeutics | $165.53 | 2023-2025 | Korlym |
| Dexcom, INC. | $158.45 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $151.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $131.03 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $125.66 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.